Bayer HealthCare Pharmaceuticals

Type: Company

Name: Bayer HealthCare Pharmaceuticals

First Reported Mar 16 2010 - Updated Mar 17 2010 - 2 Documents

Onyx Pharmaceuticals to Present at the Barclays Capital 2010 Glob...

Company: Onyx Pharmaceuticals, Inc. (ONXX) Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific ... [Published Mar 17 2010 by Zibb]

Entities: Onyx Pharmaceuticals Inc, Nexavar, Barclays Capital Inc, Bayer HealthCare Pharmaceuticals

First Reported Mar 15 2010 - Updated Mar 15 2010 - 1 Documents

FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxaci

Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary infection due to Pseudomonas aeruginosa ... [Published Mar 15 2010 by PR-USA.net]

Entities: Bayer HealthCare Pharmaceuticals, Cystic Fibrosis, Orphan Drug

First Reported Mar 11 2010 - Updated Mar 12 2010 - 5 Documents

Food and Drug Administration

Bayer obtains FDA orphan drug designation for cystic fibrosis drug

Bayer HealthCare Pharmaceuticals has reported that an orphan drug designation has been granted by the FDA for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis, or CF, patients.Ciprofloxacin ... [Published Mar 12 2010 by TradingMarkets]

Entities: Orphan Drug, Cystic Fibrosis, Food and Drug Administration, Bayer AG, Novartis AG

First Reported Mar 11 2010 - Updated Mar 11 2010 - 1 Documents

Bayer AG

Bayer lung infection drug gets orphan status

Bayer HealthCare Pharmaceuticals said Thursday that it received orphan status for an inhaled drug intended to treat lung infections in cystic fibrosis patients.Orphan drug status is granted by the Food and Drug Administration for drugs intended to treat ... [Published Mar 11 2010 by Research & Development]

Entities: Bayer AG, Infection, Cystic Fibrosis

First Reported Mar 10 2010 - Updated Mar 10 2010 - 1 Documents

AHRA 2010 Fall Conference

The AHRA Fall Conference, in collaboration with Bayer HealthCare Pharmaceuticals, is one of the industry’s premier events for medical imaging professionals. As a speaker, you will enjoy the prestige and satisfaction of presenting to the most active and ... [Published Mar 10 2010 by Medicexchange.com]

Entities: Bayer HealthCare Pharmaceuticals, Radiology, Business Plan

First Reported Mar 06 2010 - Updated Mar 06 2010 - 1 Documents

Billy Tauzin

National Roundup: Lilly Expands Disease Management Program to Reach Growing ...

Pharmaceutical Research Companies Donate $35Million to Relief Efforts in Haiti; More Help ComingAs the need for health care assistance mounts after the recent catastrophic earthquake in Haiti, America's pharmaceutical research and biotechnology companies ... [Published Mar 06 2010 by Community Pharmacist]

Entities: Haiti, Billy Tauzin, Eisai Inc., MAP International

First Reported Mar 01 2010 - Updated Mar 01 2010 - 1 Documents

Bayer HealthCare Pharmaceuticals' RECOTHROM solution receives Health Canada approval

RECOTHROM(R) provides an aid to hemostasis on demand, allowing surgeons to deal with bleeding and complete the surgical procedureBayer HealthCare Pharmaceuticals announced today that RECOTHROM(R) (Thrombin alfa (Recombinant)), the first recombinant, plasma-free ... [Published Mar 01 2010 by News-Medical.Net]

Entities: Bayer HealthCare Pharmaceuticals, Health Canada, Recombinant, Thrombin

First Reported Feb 23 2010 - Updated Feb 24 2010 - 1 Documents

Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the full year and fourth quarter 2009. Global Nexavar net sales as recorded by Onyx's collaborator, Bayer HealthCare Pharmaceuticals, Inc., or Bayer, were $843.5 million ... [Published Feb 23 2010 by Individual.com]

Entities: Onyx Pharmaceuticals Inc, Nexavar, Bayer AG, Bayer HealthCare Pharmaceuticals

First Reported Dec 11 2009 - Updated Dec 12 2009 - 1 Documents

Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies

See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News, Clinical Trials & Medical Discoveries- Data Presented at 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium -WAYNE, N.J. and EMERYVILLE, ... [Published Dec 11 2009 by PR Newswire]

Entities: Nexavar, Breast Cancer, Placebo, Bayer HealthCare Pharmaceuticals, PHASE 2

First Reported Dec 09 2009 - Updated Dec 09 2009 - 1 Documents

Bayer's Multimillion-Dollar MRI-Related Drug to Get Its First Trial Test

Early signs of how each side could fare at trial in hundreds of suits over contrasting agents that allegedly cause nephrogenic systemic fibrosis are expected to come out of a California court. A suit against Bayer Healthcare Pharmaceuticals has been ... [Published Dec 09 2009 by Law.com - Newswire]

Entities: Bayer AG, Bayer HealthCare Pharmaceuticals, fibrosis, Superior Court

First Reported Nov 03 2009 - Updated Nov 03 2009 - 1 Documents

Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the third quarter 2009. Global Nexavar net sales as reported by Onyx's collaborator Bayer HealthCare Pharmaceuticals, ... [Published Nov 03 2009 by Financial Services]

Entities: Nexavar, Onyx Pharmaceuticals Inc, Bayer AG, Bayer HealthCare Pharmaceuticals, Emeryville (United States)

First Reported Oct 24 2009 - Updated Oct 24 2009 - 1 Documents

Bayer, Onyx begin phase-3 trial of Nexavar in patients with non-responsive thyroid cancer

Bayer HealthCare Pharmaceuticals, Inc and Onyx Pharmaceuticals, Inc announced the companies have begun enrolling patients in an international phase-3 trial to evaluate Nexavar (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, ... [Published Oct 24 2009 by PharmaBiz]

Entities: Thyroid neoplasm, Nexavar, Bayer AG, Bayer HealthCare Pharmaceuticals

Quotes

...with cystic fibrosis,' said Shannon Campbell, Vice President and General Manager, Oncology and General Medicine, Bayer HealthCare Pharmaceuticals. "We are pleased to receive the orphan drug designation from the FDA for ciprofloxacin DPI, which we are researching as a potential treatment option for management of pulmonary infections due to P aeruginosa in CF patients."

FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxaci [PR-USA.net - Mar 15 2010]

More Content

sort by: Date \| Relevance
Pediatric Exclusivity Granted [U.S. Food and Drug Administration - 6 hours ago]
Onyx Pharmaceuticals to Present at the Barclays... [Zibb - Mar 17 2010]
Onyx Pharmaceuticals to Present at the Barclays... [FinanzNachrichten.de - Mar 16 2010]
FDA Grants Bayer HealthCare Pharmaceuticals Orp... [PR-USA.net - Mar 15 2010]
Bayer obtains FDA orphan drug designation for c... [TradingMarkets - Mar 12 2010]
Bayer HealthCare Pharma Receives ODD For Ciprof... [Pharmaceutical Business Review - Mar 12 2010]
Bayer HealthCare Pharmaceuticals' ciprofloxacin... [News-Medical.Net - Mar 12 2010]
Bayer receives orphan drug designation for CF t... [Drug Store News - Mar 12 2010]
Bayer lung infection drug gets orphan status [Research & Development - Mar 11 2010]
FDA Grants Bayer HealthCare Pharmaceuticals Orp... [Forbes.com - Mar 11 2010]
Bayer HealthCare Pharmaceuticals (BAY) Receives... [Street Insider - Mar 11 2010]
BayBio Introduces New Chief Operating Officer [FinanzNachrichten.de - Mar 10 2010]
AHRA 2010 Fall Conference [Medicexchange.com - Mar 10 2010]
New and Generic Drug Approvals [U.S. Food and Drug Administration - Mar 09 2010]
Pharmas heed FDA warnings [Drug Discovery News - Mar 09 2010]
National Roundup: Lilly Expands Disease Managem... [Community Pharmacist - Mar 06 2010]
Bayer HealthCare Pharmaceuticals' RECOTHROM sol... [News-Medical.Net - Mar 01 2010]
Acorda Therapeutics Taps Adrian Rabinowicz as S... [TradingMarkets - Feb 25 2010]
Onyx Pharma Q4 Loss Narrows On Higher Nexavar S... [RTTNews.com - Feb 23 2010]
Onyx Pharmaceuticals Reports Record Full Year a... [Individual.com - Feb 23 2010]
Acorda Therapeutics Announces Adrian L. Rabinow... [Business Wire via MSN Money - Feb 22 2010]
Onyx Pharmaceuticals Announces Fourth Quarter a... [Forbes.com - Feb 16 2010]
Bayer Consolidation Benefits Omnicom, WPP [Adweek Online - Feb 11 2010]
Sorafenib Combo Holds Promise in Metastatic Bre... [Pharmacy Practice News - Feb 11 2010]
America's Pharmaceutical Research Companies Don... [PR Newswire - Jan 29 2010]
Nexavar in Combination With Chemotherapy Demons... [PR Newswire - Dec 11 2009]
Bayer's Multimillion-Dollar MRI-Related Drug to... [Law.com - Newswire - Dec 09 2009]
Reportlinker Adds Radiopharmaceuticals - A US a... [PR Newswire - Dec 08 2009]
Onyx Pharmaceuticals Reports Third Quarter 2009... [Financial Services - Nov 03 2009]
Bayer, Onyx begin phase-3 trial of Nexavar in p... [PharmaBiz - Oct 24 2009]

Advanced Search Options

Bayer HealthCare Pharmaceuticals